271 related articles for article (PubMed ID: 17519150)
1. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
Coffee AL; Sulak PJ; Kuehl TJ
Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
[TBL] [Abstract][Full Text] [Related]
2. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen.
Sulak PJ; Kuehl TJ; Coffee A; Willis S
Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
4. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.
Sulak P; Willis S; Kuehl T; Coffee A; Clark J
Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491
[TBL] [Abstract][Full Text] [Related]
5. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
[TBL] [Abstract][Full Text] [Related]
6. A look at the long-term safety of an extended-regimen OC.
Davis MG; Reape KZ; Hait H
J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
[TBL] [Abstract][Full Text] [Related]
7. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ
J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649
[TBL] [Abstract][Full Text] [Related]
8. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
9. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ
Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834
[TBL] [Abstract][Full Text] [Related]
10. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days.
Foidart JM; Sulak PJ; Schellschmidt I; Zimmermann D;
Contraception; 2006 Jan; 73(1):34-40. PubMed ID: 16371292
[TBL] [Abstract][Full Text] [Related]
11. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Gerlinger C; Kunz M
Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
[TBL] [Abstract][Full Text] [Related]
12. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
Jensen JT; Garie SG; Trummer D; Elliesen J
Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
[TBL] [Abstract][Full Text] [Related]
13. [Combined hormonal contraception in cycles artificially extended].
Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding.
Sulak PJ; Carl J; Gopalakrishnan I; Coffee A; Kuehl TJ
Contraception; 2004 Oct; 70(4):281-7. PubMed ID: 15451331
[TBL] [Abstract][Full Text] [Related]
15. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
16. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
Kaunitz AM; Portman DJ; Hait H; Reape KZ
Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846
[TBL] [Abstract][Full Text] [Related]
17. The effects of oral contraceptives on androgen levels and their relevance to premenstrual mood and sexual interest: a comparison of two triphasic formulations containing norgestimate and either 35 or 25 microg of ethinyl estradiol.
Greco T; Graham CA; Bancroft J; Tanner A; Doll HA
Contraception; 2007 Jul; 76(1):8-17. PubMed ID: 17586130
[TBL] [Abstract][Full Text] [Related]
18. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
Chaiyasit N; Taneepanichskul S
J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
[TBL] [Abstract][Full Text] [Related]
19. Bleeding patterns and menstrual-related symptoms with the continuous use of a contraceptive combination of ethinylestradiol and drospirenone: a randomized study.
Machado RB; de Melo NR; Maia H
Contraception; 2010 Mar; 81(3):215-22. PubMed ID: 20159177
[TBL] [Abstract][Full Text] [Related]
20. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
Barbosa IC; Filho CI; Faggion D; Baracat EC
Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
